三元基因
(837344)
| 流通市值：21.89亿 | | | 总市值：23.48亿 |
| 流通股本：1.14亿 | | | 总股本：1.22亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 47,952,373.12 | 244,732,951.33 | 152,405,009.18 | 100,209,522.13 |
| 营业收入 | 47,952,373.12 | 244,732,951.33 | 152,405,009.18 | 100,209,522.13 |
| 二、营业总成本 | 46,920,517.51 | 209,869,414.6 | 142,966,059.86 | 90,560,359.72 |
| 营业成本 | 9,185,324.05 | 49,711,672.95 | 31,591,122.61 | 21,290,487.97 |
| 税金及附加 | 1,180,038.31 | 2,022,117.4 | 1,389,713.53 | 927,544.51 |
| 销售费用 | 23,449,038.47 | 113,169,553.36 | 75,873,067.08 | 47,490,605.85 |
| 管理费用 | 8,891,814.59 | 31,269,553.92 | 22,539,738.72 | 14,519,669.85 |
| 研发费用 | 2,924,856.44 | 13,079,346.1 | 10,987,680.55 | 6,245,500.9 |
| 财务费用 | 1,289,445.65 | 617,170.87 | 584,737.37 | 86,550.64 |
| 其中:利息费用 | 1,747,969.35 | 2,524,664.99 | 2,005,544.9 | 1,071,617.49 |
| 其中:利息收入 | 464,427.2 | 1,934,174.57 | 1,440,402.46 | 997,932.55 |
| 资产处置收益 | - | 0 | - | - |
| 资产减值损失(新) | -5,040.72 | -1,111.23 | -414.87 | 0 |
| 信用减值损失(新) | 734,025.45 | -1,921,791.08 | -556,503.56 | -807,141.9 |
| 其他收益 | 479,528.82 | 3,094,070.98 | 2,871,617.06 | 2,277,228.28 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 2,240,369.16 | 36,034,705.4 | 11,753,647.95 | 11,119,248.79 |
| 加:营业外收入 | 7.47 | 2,893.17 | 2,116.42 | 1,401.05 |
| 减:营业外支出 | 4,895.75 | 423,166.22 | 21,616.68 | 19,750.48 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 2,235,480.88 | 35,614,432.35 | 11,734,147.69 | 11,100,899.36 |
| 减:所得税费用 | 307,082.7 | 3,932,714.76 | 790,736.13 | 1,886,603.05 |
| 六、净利润 | 1,928,398.18 | 31,681,717.59 | 10,943,411.56 | 9,214,296.31 |
| 持续经营净利润 | 1,928,398.18 | 31,681,717.59 | 10,943,411.56 | 9,214,296.31 |
| 归属于母公司股东的净利润 | 1,928,398.18 | 31,681,717.59 | 10,943,411.56 | 9,214,296.31 |
| (一)基本每股收益 | 0.02 | 0.26 | 0.09 | 0.08 |
| (二)稀释每股收益 | 0.02 | 0.26 | 0.09 | 0.08 |
| 九、综合收益总额 | 1,928,398.18 | 31,681,717.59 | 10,943,411.56 | 9,214,296.31 |
| 归属于母公司股东的综合收益总额 | 1,928,398.18 | 31,681,717.59 | 10,943,411.56 | 9,214,296.31 |
| 公告日期 | 2024-04-26 | 2024-04-15 | 2023-10-30 | 2023-08-25 |
| 审计意见(境内) | | 标准无保留意见 | | |